Cardiovascular Digital Solutions Market Share

North America Market Statistics

North America cardiovascular digital solutions market is predicted to hold revenue share of over 33.2% by the end of 2037, owing to the rising prevalence of cardiac diseases, the presence of well-developed healthcare infrastructure, and increasing product launches and approvals for cardiovascular health.

The U.S. market is expected to expand at a robust rate during the forecast period. According to statistics released by the Centers for Disease Control and Prevention, CVD accounted for 37% of all deaths in the U.S. in 2021. With an emphasis on preventive care and shifting healthcare approaches towards a more preventive course, the need for sophisticated digital technologies has increased to monitor and track patients, advance early diagnosis, and reinforce the efficiency of treatments in the U.S.

In Canada, the cardiovascular digital solutions market is poised to register rapid growth between 2025 and 2037 owing to the rising incidence of heart diseases and increasing adoption of advanced digital healthcare. Companies are also focusing on developing advanced products and digital solutions for cardiac care. For instance, CIFAR launched two AI health solutions to cater to rising health problems in Canada, including cardiovascular diseases.

Asia Pacific Market Analysis

Asia Pacific cardiovascular digital solutions market is expected to expand at a robust CAGR during the forecast period owing to rising prevalence of cardiovascular diseases, hypertension, and diabetes, the high adoption of unhealthy lifestyles, and the rapid adoption of advanced cardiovascular digital solutions across several healthcare sectors. Moreover, the integration of AI, ML, and telemedicine in cardiovascular care solutions is expected to further accelerate market growth in the Asia Pacific.

In India, the cardiovascular digital solutions market is expected to register a rapid revenue CAGR between 2025 and 2037. This growth can be attributed to the high prevalence of heart diseases, rapid adoption of advanced healthcare technologies, and rising awareness about the importance of early detection and diagnosis. Companies are also investing in R&D investments to launch novel and effective cardiovascular digital solutions. In January 2023, Lupin Digital Health announced the launch of LYFE, a digital therapeutic solution for heart care. This solution is currently available in 10 cities, designed to reduce the risk of heart disease and enhance the quality of life of patients.

The cardiovascular digital solutions market in China is anticipated to expand at a rapid growth during the forecast period owing to the presence of robust healthcare infrastructure, rising prevalence of various cardiovascular diseases, and rising investments in R&D activities. For instance, in April 2020, Novartis launched a novel AI-enabled disease management tool in China to improve the rate of heart failure in the country.